Summary JM216 (bis-acetato ammine dichloro cyclohexylamine Pt IV) is an oral platinum complex presently undergoing phase II clinical trials. Previous studies have identified some of its biotransformation products in clinical materials. This study evaluated the nature of JM216 biotransformation products intracellularly in two different human ovarian carcinoma cell lines, one relatively sensitive to platinum agents (CH1: JM216 4 h IC50 of 5.8 gM) and the other relatively resistant (SKOV3: JM216 4 h IC50 of 60.7 gM). Metabolic profiles were also evaluated at different growth status and in cells pretreated with buthionine sulphoximine (BSO), an agent known to decrease intracellular glutathione levels. Results showed that JM216 enters the cells and that the nature and percentage of biotransformation products was dependent upon glutathione levels. Furthermore, results support the view that the previously reported peak A biotransformation product contains a glutathione adduct. In exponentially growing SKOV3 cells which contain higher glutathione levels than CHI, (82.5 vs 37.8 nmol mg-' protein), peak A represented 89% of total platinum 4 h after JM216 exposure compared with only 24% in CHI. Moreover, 60-70% depletion of glutathione achieved by 24 h pretreatment of cells with BSO resulted in a significant decrease in peak A in both cell lines and increased the cytotoxicity of JM216 in both CHI and SKOV3 by approximately 2-fold. Following a 4 h exposure of exponentially growing SKOV3 cells to JM216, only peak A (89%) and JM216 (11%) could be detected whereas in CHI cells, peak A (24%), JM216 (73%) and JM118 [cis-ammine dichloro (cyclohexylamine) platinum II] (3%) were detected. However, in CH1 cells at confluence, where glutathione is lower (8 nmol mg-' protein) four metabolites (plus JM216 itself) were detected following exposure to 50 tM JM216; peak A, JM1 18, JM383 (bis-acetato ammine (cyclohexylamine) dihydroxy platinum IV) and an unidentified metabolite (D), also observed in patient's plasma ultrafiltrate. In confluent SKOV3 cells exposed to 50 pM JM216, peak A, JM216 and JM1 18 were detected. A further unidentified metabolite observed in patients receiving JM216 (metabolite F) was not formed inside these tumour cells. Overall, these data suggest that glutathione conjugation represents a major deactivation pathway for JM216.
JM216 is a platinum IV ammine/amine dicarboxylate that has shown high in vitro activity in a panel of human ovarian carcinoma , lung cancer (Twentyman et al., 1992) , human cervical squamous cells (Mellish et al., 1993) and murine leukaemia cell lines (Orr et al., 1994) . This activity was translated in vivo in a panel of human ovarian xenograft models . JM216 showed no preclinical renal toxicity and no peripheral neuropathy (McKeage et al., , 1994a . Activity was also observed by the oral route (Giandomenico et al., 1991; Kelland et al., 1993) and, as a result, JM216 is the first orally administrable platinum complex to have entered clinical trial. It is presently undergoing phase II clinical trial in small-cell lung cancer, non-small-cell lung cancer and ovarian carcinoma. In the phase I trial, it was established that the dose-limiting toxicity is myelosuppression and the drug is well tolerated with prophylactic antiemetics . Preclinical studies have shown that multiple administrations give the best anti-tumour responses (McKeage et al., 1994b) and this has been verified in patients, where multiple administrations could overcome the saturability in absorption observed in the single-dose study (McKeage et al., 1994c; Raynaud et al., 1995) . It has been shown that JM216 is converted in patients' plasma into at least six different biotransformation complexes and that these biotransformation products are active in vitro and in vivo (Poon et al., 1995; Raynaud et al., 1996) . Three of the metabolites present in patients have not yet been identified.
Resistance to platinum agents is often multifactorial and has been described as the consequence of a cellular uptake deficiency, increased DNA repair or enhanced cellular detoxification (Richon et al., 1987; Andrews et al., 1988; Andrews and Howell, 1990; Hosking et al., 1990) . Our own previous studies have shown that in the acquired cisplatinresistant human ovarian carcinoma cell line, 4lMcisR, reduced drug accumulation is the major mechanism of resistance to cisplatin. However, some platinum IV ammine/amine complexes such as JM216 show non-crossresistance in 4lMcisR cells and accumulate as much as in the parent line (Loh et al., 1992; Sharp et al., 1995) . Glutathione or methionine conjugation is a common inactivation pathway for various nucleophiles. Glutathione has been shown to be overexpressed in numerous cell lines resistant to platinum agents and its depletion by buthionine sulphoximine (BSO) increases the cytotoxicity of platinum agents (Andrews et al., 1985; Mistry et al., 1991) . It has been demonstrated that intracellular glutathione correlates with the cytotoxicity of numerous platinum agents and more particularly Pt IV complexes (Lewis et al., 1988; Hosking et al., 1990; Mistry et al., 1991 Mistry et al., , 1993 Meijer et al., 1992) . The intracellular formation of glutathione conjugates with platinum drugs has been demonstrated with cisplatin, tetraplatin and oxaliplatin (Mistry et al., 1993; Pendyala et al., 1995) . In our metabolic studies in patients and mice plasma, a very early eluting metabolite (unidentified by mass spectroscopy) co-eluted with glutathione adducts of JM216 generated in vitro (unpublished data). It has therefore been assumed that this peak was a glutathione adduct.
The aim of this study was to characterise JM216 intracellular metabolism and to evaluate the role of glutathione in drug detoxification. Therefore, JM216 cytotoxicity and metabolism profiles were determined in two cell lines; one sensitive to platinum complexes (CH1) and one resistant to platinum complexes (SKOV3) and known to have relatively high levels of glutathione (Mistry et al., 1991) The human ovarian carcinoma cell lines used in this study were SKOV3 and CHI as described previously (Hills et al., 1989) . Cells were grown in Dulbecco's modified Eagle medium (DMEM) plus 10% fetal calf serum (FCS), 50 jMg ml-' gentamicin, 2 mM glutamine and 0.5 ig ml-' hydrocortisone at 37°C in a 10% carbon dioxide atmosphere. Cells were periodically checked and found to be free of mycoplasma and used in this study from passage 25 to 50. Cells were seeded in T175 flasks (106 cells per flask) and were allowed to attach for 24 h before drug exposure for exponentially growing cells and for 5 days for confluent cells.
Metabolic profiles
Following attachment the cells were exposed to medium containing 12.5 jiM BSO for CHI cells and 50 gM BSO for SKOV3 cells for 24 h (37°C, 10% carbon dioxide atmosphere). These doses were chosen because they have previously been shown to decrease GSH levels by over 80% in these cell lines (Mistry et al., 1991) . Control cells were exposed to medium only. JM216 (50 gM) was added to the control flasks and the BSO-treated cells and left for 1, 2 or 4 h (37°C, 10% carbon dioxide atmosphere). The medium was then removed and cells were washed twice with PBS. After the medium was removed, the cells were washed three times with ice-cold PBS and then scraped and harvested in 2 x 0.5 ml PBS. The suspension was then sonicated (polytron sonicator MSE Fisons Ltd) for 2 x 15 s at 14 mAmps. An aliquot of the cell sonicate was taken for protein analysis; the remainder was ultrafiltered using Amicon 10 000 MW exclusion membranes (4800 r.p.m. 45 min at 40C) and stored in liquid nitrogen until analysis. JM216 metabolites were separated by high performance liquid chromatography (HPLC) on a polymeric phase column (PLRP-S). Samples (200 Ml) were injected and eluted with a water/acetonitrile linear gradient (15-95% acetonitrile over 30 min). Fractions (0.2 min) were collected and platinum was evaluted in those fractions by atomic absorption spectrophotometry as described elsewhere . The identity of the metabolites was determined by co-elution with authentic standards. Structures of the various known JM216 metabolites are shown in Figure 1 .
Results
The intracellular biotransformation of JM216 in CHI cells after treatment with JM216 with or without BSO pretreatment is shown in Figure 2 (and in Figure 4 for SKOV3). In both cell lines and under all conditions, some JM216 (fraction 99-106) could be detected intracellularly (Table  I ). In exponentially growing CHI (Figure 2) , it represented 73% of ultrafiltrable platinum 4 h after treatment. Traces of JM 118 (fraction 82-90) could also be measured and an early eluting peak (A, fraction 21-36) was also seen. This peak A co-eluted with the metabolite formed when incubating JM1 18 with glutathione ( Figure 3) .
In SKOV3 exponentially growing cells (Figure 4 ), no JM118 could be detected and A represented 89% of total ultrafiltrable platinum 4 h after treatment vs only 24% in CHI (Figure 2 Cytotoxicity assay Cytotoxicity assays were performed in 96-well microtitre plates after trypsinisation with 0.02% EDTA/0.05% trypsin. Cells were plated (5000 per well for CHI and 3000-4000 per well for SKOV3). Cells were then left to attach for 24 h. In the BSO-treated cells, the cells were exposed to BSO for 24 h after attachment and before JM216 exposure while other cells were only given medium. The medium was then removed and replaced with increasing concentrations of JM216-containing medium for 2 h or 4 h (at 37°C, 10% carbon dioxide atmosphere). The JM216-containing medium was aspirated and replaced with fresh medium and the cells were left to grow for a further 96 h. Cytotoxicity was evaluated using the exposure) and increased the JM216 peak at both 1 h and 4 h after treatment (e.g. at 1 h 54-68% in CHI and 44-80% in SKOV3; at 4 h 73 -79% in CHI and 11 -30% in SKOV3) ( Table I) .
In CH1 and SKOV3 cells exposed to JM216 when confluent, the intracellular metabolic profile differed from that observed in exponentially growing cells ( Figure 5 ). In CH 1, five platinum-containing peaks could be identified (A, JM383, D, JM1 18 and JM216). D co-eluted with metabolite D observed in patients' plasma ultrafiltrates . In SKOV3, only three platinum peaks could be measured at confluence (A, JM 118 which could not be detected in exponentially growing cells and JM216). Significantly higher levels of JM 118 were observed in both lines at confluence compared with exponentially growing cells (Table I) . Glutathione levels in the different lines under the various conditions are shown in Table II . Glutathione levels were 2.2-fold higher in exponentially growing SKOV3 compared with CHI (P<0.001) and were decreased by over 60% following treatment with BSO (Table II) . In confluent cultures, the fold difference in glutathione levels was 5.7-fold. In CHI cells, the levels of glutathione 4 h after JM216 treatment were slightly decreased (but the difference was not quite significant P=0.12). In SKOV3 cells, 4 h after JM216 treatment, glutathione levels were significantly lower than in control SKOV3 cells (P<0.001).
The cytotoxicity of JM216 following 2 h or 4 h exposure and of cisplatin following 2 h exposure is shown in Table III. JM216 and cisplatin were both significantly more potent in the CHI line compared with the SKOV3 (P<0.001). Following 2 h drug exposure in the SKOV3 cells, the cytotoxicity of both drugs was increased by approximately 2-fold by the BSO pretreatment, while in the CHI cell line only JM216 cytotoxicity was affected by BSO (again by approximately 2-fold). Following 4 h exposure to JM216, the cytotoxicity data were not significantly different from that following 2 h exposure (Table III) . inactivation (Andrews & Howell, 1990; Eastman 1987a,b; Masuda et al., 1988; Loh., 1992) . Glutathione, the predominant intracellular non-protein thiol, provides a major defence against electrophiles. Increased glutathione levels are a common feature in cellular resistance against (Mellish and Kelland, 1994) and levels of glutathione have been shown to correlate with sensitivity to platinum agents in human and murine tumour cells (Hosking et al., 1990; Mistry et al., 1991; Meijer et al., 1992) . Depletion of glutathione with BSO has previously been shown to correlate with sensitivity to platinum drugs, particularly platinum (IV) complexes (Mistry et al., 1991 (Mistry et al., , 1993 Meijer et al., 1992; Pendyala et al., 1995) . This work supports the view that glutathione conjugation is an important inactivation pathway for JM216. Furthermore, it shows that in our experimental conditions, JM216 enters the cells and its converted to a variety of metabolites (A, JM383, D and JM118).
Our results also support the notion that peak A includes a glutathione adduct. Hence the percentage of A decreases when the cells are treated with BSO and is higher in cells (SKOV3) with higher glutathione concentrations. Furthermore, the glutathione levels decrease in both cell lines following JM216 treatment. Levels of glutathione can influence both the nature of the metabolic profile and, consequently, the cytotoxicity of JM216. In our experimental conditions, cell density clearly affected both the glutathione content and the metabolic profiles. Previous studies have demonstrated that growth status affects the cellular levels of glutathione (Batist et al., 1986; Post et al., 1983) . In exponentially growing cells, only the parent drug, the glutathione adduct and, for CHI, traces of JM118, could be detected in cell ultrafiltrates, while five metabolites could be detected in confluent cells including significant levels of JM 118. This could be a consequence of a higher trapping of these metabolites by glutathione in exponentially growing cells or could also be caused by the effect of glutathione on DNA repair. Indeed, glutathione has been shown to facilitate DNA repair in cell lines with acquired resistance to cisplatin, but the mechanism is still poorly understood Rairkar and Ali-Osman; . In our experimental conditions BSO pretreatment increased the intracellular free platinum levels in the resistant SKOV3 cells. As little difference in JM216 intracellular uptake has been observed at an equimolar dose of 50 gM (CF O'Neill, personal communication) , and no difference in overall DNA platination at equimolar doses is seen (Mellish et al., 1995) , our data suggest that other forms of interactions (proteins) might be relevant in these cells. Previous studies have demonstrated that, in certain cell lines, glutathione conjugates may be excreted by an energy-dependent pump which is overexpressed in at least some cells resistant to platinum agents (Ishikawa et al., 1993 (Ishikawa et al., , 1994 . Further studies suggest that this pump may be related to the MRP-associated protein (Muller et al., 1994; Versanvoort et al., 1995) . However, we have not been able to detect MRP in SKOV3 cells (SY Sharp, personal communication) .
The intracellular profiles observed following JM216 administration show the formation of a variety of metabolites (A, JM383, D and JM 118) and indicate that JM216 enters the cells. Another platinum (IV) complex, tetraplatin, tetrachloro (D,L, -trans)1,2 diaminocyclohexaneplatinum (IV) (ormaplatin), was shown to be reduced very rapidly in tissue culture medium to dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II) (Gibbons et al., 1989) , while iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV)] was reduced intracellularly to cisdichloro-bis-isopropylamine platinum (II) (Pendyala et al., 1989 ). In our experimental conditions, it is not clear whether the reduction of JM216 occurs intracellularly or extracellularly.
Our results show that some metabolites previously observed in patients' plasma ultrafiltrates can be observed intracellularly; those being A, JM383, D and JM 118 (Raynaud et al., , 1996 . However, JM216 itself was never detected in patients' plasma ultrafiltrates and a late eluting metabolite F was not seen intracellularly and no JM559 could be measured.
The fact that JM216 was active in mice bearing human ovarian xenografts, where it also becomes biotransformed (unpublished results), suggests that cytotoxic species enter the cells. We have also previously shown that JM216 metabolites show significant cytotoxicity (Raynaud et al., 1996) . Our results might indicate that the cytotoxicity observed following treatment with JM216 is the result of the interaction of a variety of species with the DNA; it has recently been demonstrated that Pt (IV) complexes such as oxoplatin may generate DNA adducts directly (Novakova et al., 1995) .
In conclusion, this work shows that glutathione levels drive intracellular JM216 metabolism. When glutathione levels are low, more biotransformation products are formed inducing higher cytotoxicity. Trapping by glutathione reduces both the number and the relative amount of parent, and cytotoxic metabolites, thereby decreasing cytotoxicity.
